U.S. pharma giant copyright scrapped two experimental weight loss drugs last yr—a at the time-everyday tablet, lotiglipron, on account of elevated liver enzymes in addition to a twice-each day capsule, danuglipron, resulting from strong Unwanted effects—but CEO Albert Bourla has reported the company is decided to “Participate in and get” in